-
February 22, 2020
Data Favor Max Resection for All Glioblastomas Bookmark
George Lundberg, MDArticle from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes:
A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.
Go to full article published by MedPage Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 31, 2020
FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian Cancer Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
In precision oncology, drugs combinations may provide new effective treatment.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 10, 2020
Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer Patients
Lola Rahib, PhDIn collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for pancreatic cancer patients at a conference in San Diego, CA, today. The “Special Conference on Advancing Precision Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies” is hosted by the… Read more »
-
January 7, 2020
FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer Bookmark
George Lundberg, MDArticle from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.
Go to full article published by The Cancer Letter.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 26, 2019
Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer Bookmark
George Lundberg, MDArticle from the National Cancer Institute curated by Editor in Chief George Lundberg, MD, who notes:
In 2019, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for certain advanced esophageal cancers, depending on testing results. The National Cancer Institute explains here.
Go to full article published by the National Cancer Institute.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 23, 2019
Renal Cell Cancer Treatment: The Old, the Almost Old, and the New
Emma Shtivelman, PhDClear cell renal cell cancer (ccRCC) is the predominant type of kidney cancer, accounting for 70% to 75% of all kidney cancers. Here, I outline the current treatment landscape for ccRCC, highlighting what’s new and what’s on the horizon. Surgical removal of the cancerous kidney is most often the first treatment after diagnosis, especially if the tumors exceed 3- to 4 cm in size.… Read more »
-
December 13, 2019
New Standard of Care for Metastatic Renal Cell Carcinoma Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
This piece describes huge improvements in the standard of care and outcomes from combo therapy in metastatic renal cell carcinoma.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
Plasmacytoid Urothelial Carcinoma: An Unusual Variant That Warrants Aggressive Management and Critical Distinction on Transurethral Resections Bookmark
George Lundberg, MDResearch paper from the Archives of Pathology & Laboratory Medicine curated by Editor in Chief George Lundberg, MD, who notes:
Plasmacytoid urothelial carcinoma merits special aggressive therapy.
Go to full paper published in the Archives of Pathology & Laboratory Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Secondary Surgical Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
Chemotherapy alone bests cytoreductive surgery plus chemotherapy in recurrent ovarian cancer.Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Clinical Impact of New Data in B-Cell Malignancies From 2019 EHA and ICML Bookmark
George Lundberg, MDContinuing medical education course from Clinical Care Options curated by Editor in Chief George Lundberg, MD, who notes:
Recent research findings can change practices for B-cell malignancies.
Go to educational module at Clinical Care Options (requires free registration).
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Treatment Options
Learn about the latest treatments for advanced cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, cancer vaccines, modified viruses, and more.
